Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients
Authors:
Open Access
- 19 October 2014
- journal article
- research article
- Published by Springer Nature in Quality of Life Research
- Vol. 24 (3) , 591-598
Abstract
Purpose To construct a model to predict preference-adjusted EuroQol 5D (EQ-5D) health utilities for patients with metastatic castrate-resistant prostate cancer (mCRPC) using the disease-specific health-related quality of life (HRQoL) measure, functional assessment of cancer therapy-prostate (FACT-P). Methods HRQoL data were collected from patients with mCRPC who were enrolled in an observational study conducted in 47 centers across six European Union countries. Utility values were generated using a UK-specific EQ-5D value set. The predictive validity of the five FACT-P subscales, patient demographics, comorbidities and prior chemotherapy was tested using ordinary least squares (OLS), median, Gamma and Tobit multivariate regression models. Results FACT-P and EQ-5D questionnaires were completed by 602 (86 %) patients. Mean age [standard deviation (SD)] was 72.1 (7.9) years, mean time from diagnosis (SD) was 5.4 (4.4) years, and mean time since failure of androgen deprivation therapy (SD) was 1.0 (1.6) years. At study inclusion, 39 % of patients were chemotherapy-naïve, 37 % were undergoing chemotherapy, and 24 % were post-chemotherapy. Mean FACT-P and EQ-5D utility values were 104 and 0.66, respectively. OLS regression was the best-performing model, explaining 61.2 % of the observed EQ-5D variation. All FACT-P subscales were significantly predictive; the physical and functional well-being subscales had the highest explanatory value (coefficient 0.023 and 0.001, respectively, p < 0.0001). The other variables did not add additional explanatory value. Conclusions The algorithm developed enables translation of cancer-specific HRQoL measures to preference-adjusted health status in patients with mCRPC. The function may be useful in calculating EQ-5D scores when EQ-5D data have not been gathered directly.Keywords
This publication has 21 references indexed in Scilit:
- Review of studies mapping from quality of life or clinical measures to EQ-5D: an online databaseHealth and Quality of Life Outcomes, 2013
- Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patientsHealth and Quality of Life Outcomes, 2012
- Mapping onto Eq-5 D for patients in poor healthHealth and Quality of Life Outcomes, 2010
- A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measuresThe European Journal of Health Economics, 2009
- Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?Health and Quality of Life Outcomes, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Mapping FACT-P and EORTC QLQ-C30 to Patient Health Status Measured by EQ-5D in Metastatic Hormone-Refractory Prostate Cancer PatientsValue in Health, 2007
- Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step BackwardsClinical Cancer Research, 2005
- A Comparison of Methods for Analyzing Health-Related Quality-of-Life MeasuresValue in Health, 2002
- Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrumentUrology, 1997